2021
843. Targeted HIV Testing for Patients Hospitalized for COVID-19
Virata M, Villanueva M, Miceli J. 843. Targeted HIV Testing for Patients Hospitalized for COVID-19. Open Forum Infectious Diseases 2021, 8: 512-512. PMCID: PMC8643876, DOI: 10.1093/ofid/ofab466.1038.Peer-Reviewed Original ResearchYale New Haven Health SystemHIV risk factorsCOVID-19 infectionHIV testingSARS-CoV-2Comorbidity scoreRisk factorsProtease inhibitorsUse of PIsAppropriate HIV treatmentComorbidity of HIVHIV testing resultsMajority of PWHPerformance of HIVTargeted HIV TestingElixhauser comorbidity scoreSubset of patientsLimited clinical dataSevere respiratory illnessHIV infection ratesSpecific underlying conditionLarge healthcare systemCOVID-19Chi-squared analysisComplicated diabetes
2017
Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
Ogbuagu O, Hao R, Virata M, Villanueva M, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Research 2017, 6: 620. DOI: 10.12688/f1000research.11397.1.Peer-Reviewed Original ResearchHCV genotype 1 infectionGenotype 1 infectionHCV viral loadSOF/LDVViral loadSVR 12Treatment regimenGenotype 1Sustained virologic response 12 weeksYale New Haven Health SystemIU/HCV co-infected patientsVirologic response 12 weeksCo-infected patientsHCV treatment regimenMono-infected patientsSimilar viral loadsCompletion of therapyHCV genotype 1HIV viral loadSame treatment regimenSofosbuvir/ledipasvirStudy eligibility criteriaAntiretroviral therapyHCV infection